The Best Medicines Coalition is a national alliance of patient organizations with a shared goal of equitable and consistent access for all Canadians to safe and effective medicines that improve patient outcomes. The BMC’s areas of interest include drug approval, assessment and reimbursement, as well as patient safety and supply issues. As an important aspect of its work, the BMC strives to ensure that Canadian patients have a voice and are meaningful participants in health policy development, specifically regarding pharmaceutical care.

The BMC’s core activities involve issue education, consensus building, planning and advocacy, making certain that patient-driven positions are communicated to decision makers and other stakeholders.

The BMC was formed in 2002 as a grassroots alliance of patient advocates. In 2012, the BMC was registered under the Not-for-profit Corporations Act. The organization is governed by By-Laws and a Board of Directors. At each Annual General Meeting, attended by representatives of member organizations, an Annual Chair’s Report is presented which reviews governance, membership changes, financial issues and highlights of the work of the BMC.


The BMC is committed to ensuring that all Canadians have safe and timely access to medications which have been shown, based on best available evidence, to improve outcomes for patients.


  • Drug programs which deliver high standards of equitable and consistent access to medications for all Canadians.
  • Drug review and post-marketing surveillance systems to address patient safety; knowledge of risks and benefits throughout drug lifecycle.
  • Effective models for meaningful and equitable patient participation in drug reviews and policy development.